ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Tozasertib + cisplatin inhibits proliferation, migration, and induces apoptosis in esophageal carcinoma cells.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal cancer is a highly aggressive malignancy with limited treatment options. Cisplatin (CDDP)-based chemotherapy is often restricted by the development of drug resistance and systemic toxicity. Aurora kinase inhibitors have emerged as promising chemosensitizers in various cancers.
objectiveIt was to investigate the impact of the kinase inhibitor Tozasertib (VX-680) on the extracellular signal-regulated kinase (ERK) pathway and its synergistic mechanism with cisplatin (CDDP) in inducing senescence in esophageal cancer cells.
methodsExperiments were conducted using human esophageal cancer cell lines TE-1 and KYSE150, with the following groups: blank control, Tozasertib monotherapy, CDDP monotherapy, Tozasertib combined with CDDP, and a positive control group of CDDP + 5-fluorouracil (5-FU) (3 μM CDDP + 30 μM 5-fluorouracil). Cell proliferation, migration, and apoptosis, and protein levels of all groups were compared and analyzed.
resultsTozasertib + CDDP group (0.08 μM Tozasertib + 0.75 μg/mL CDDP) demonstrated significantly reduced cell proliferation rates (41.6% ± 2.9% in TE-1 cells and 38.2% ± 3.1% in KYSE150 cells) and migration rates (7.3% ± 1.8% in TE-1 and 8.5% ± 1.4% in KYSE150), with superior efficacy compared to monotherapy groups (P < 0.05). The Tozasertib + CDDP group exhibited the highest apoptosis rate at 48 h (TE-1: 44.6% ± 4.5%; KYSE150: 42.3% ± 4.4%, P < 0.05). Conditioned medium from the Tozasertib + CDDP group showed the strongest inhibitory effect on human umbilical vein endothelial cell (HUVEC) tube formation (total tube length: 3220 ± 401 pixels for TE-1-derived and 3390 ± 388 pixels for KYSE150-derived, P < 0.01). Western blot analysis revealed significant upregulation of cleaved PARP and cleaved caspase-3 (P < 0.05), along with marked downregulation of pro-caspase-3, phosphorylated ERK (p-ERK), matrix metalloproteinase-2 (MMP-2), vascular endothelial growth factor (VEGF), Cyclin B1, and c-Myc expression (P < 0.05) in the Tozasertib + CDDP group.
conclusionIn summary, aurora kinase inhibitor combined with CDDP could suppress the ERK pathway to affect the biological process of esophageal carcinoma cells. Versus a simple drug, a drug combination could effectively inhibit the proliferation and migration of esophageal carcinoma cells, promote apoptosis, reduce angiogenesis, and induce cell cycle arrest.
Indexed as
Identifiers
42043774What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.